Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ESMO 2026
Biotech
After Enhertu: The slow hunt for next-gen HER2 breast cancer drugs
From dual-payload ADCs to bispecifics and radioligands, drugmakers are hunting for answers either after Enhertu progression or to replace it.
Angus Liu
Oct 28, 2026 9:00am
From RAS rivalry to leaked readouts, ESMO brought the data drama
Oct 27, 2026 8:00am
ESMO: Incyte claims ‘neck and neck’ KRAS G12D race with RevMed
Oct 26, 2026 9:45am
Tango trims headcount after showcasing RevMed combo's potential
Oct 26, 2026 5:06am
ESMO: AZ exec insists ph. 3 ADC data ‘robust’ despite PFS miss
Oct 25, 2026 11:30am
ESMO: Roche touts ‘convincing’ KRAS data after phase 3 win
Oct 25, 2026 11:30am
